Synthetic data only. Never enter patient information; nothing is sent or stored. For clinicians. Not FDA cleared.

CPE-006 · synthetic case TESTO-FX-06

Headache, visual field loss and prolactin 310

Possible pituitary mass effect.

Synthetic · no real patientAuthored by Biod · reviewed by Dr. AmaralTestosterone engine v1.0.0

Purpose: Possible pituitary mass effect.

Inputs the engine received

Testosterone and hormones

Total testosterone, sample 1
90 ng/dL
Prolactin
310 ng/mL

Symptoms and findings

Age
37 years
Low libido
Yes
Severe headache or visual field loss
Yes

What the engine reports

Priority

Raised prolactin with low testosterone

HG-07

A raised prolactin can suppress testosterone and may reflect a pituitary lesion, medication or another cause. Consider pituitary imaging when it is clearly raised, review prolactin-raising drugs, hypothyroidism and macroprolactinemia, and address the cause before testosterone therapy is weighed.

Detected clinical pattern

Urgent Review Finding

A safety rule calls for urgent clinical assessment. Read the safety findings first.

  • Pattern: low testosterone single sample

Why this pattern was identified

  • Low total testosterone, not confirmed. 90 ng/dL is below 300 ng/dL (AUA); second sample not entered. Confirmation on a separate fasting morning sample is required before it is acted on.

Recommended next steps

For physician consideration. Urgent review always comes first.

  1. 1Urgent assessment for a pituitary lesion.
  2. 2Consider pituitary imaging; review prolactin-raising drugs, hypothyroidism, renal failure and macroprolactinemia.
  3. 3Repeat a fasting morning total testosterone on a separate day.Endocrine Society 2018; AUA 2018.

Missing information

  • LH and FSH (to separate primary from secondary hypogonadism).
  • SHBG (for calculated free testosterone).
Evidence and rule trace · 4 rules

HG-02One low testosterone result, not yet confirmed

Inputs: total testosterone 90 ng/dL · second sample not entered

Low total testosterone on a single sample: confirmation is required.

HG-MISS-01Information needed to classify

Inputs: low testosterone · LH missing

Type of hypogonadism cannot be classified without gonadotropins and prolactin.

HG-07Hyperprolactinemia with low testosterone

Inputs: prolactin 310 ng/mL (upper limit 20) · low testosterone

Raised prolactin with low testosterone.

HG-SAFE-01Possible pituitary mass effect

Inputs: severe or new headache, or visual field loss · low testosterone

Urgent assessment: possible pituitary mass effect.

Evidence

  • EV-ES-TRT-2018 · Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
  • EV-AUA-2018 · Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432.
  • EV-ES-PRL-2011 · Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(2):273-288.

Physician adjudication required. Clinical decision support for physician review. This output identifies laboratory patterns and cautions. It does not diagnose, find the cause, or recommend starting, stopping or dosing testosterone therapy. Physician adjudication is required.

Change the values

The same engine, starting from this case. Change any value and watch the pattern and the rule trace react.

Against typical adult male reference intervals

Total testosterone (sample 1)90 ng/dL · below reference
ref 3001000
Prolactin310 ng/mL · above reference
ref 420
Testosterone and hormones
  • <264
  • 264–299
  • 300–350 borderline
  • >350

4.3 g/dL is assumed when left empty.

Symptoms and findings
Possible reversible contributors
Testosterone therapy context

Live result · computed in your browser

Priority

Raised prolactin with low testosterone

HG-07

A raised prolactin can suppress testosterone and may reflect a pituitary lesion, medication or another cause. Consider pituitary imaging when it is clearly raised, review prolactin-raising drugs, hypothyroidism and macroprolactinemia, and address the cause before testosterone therapy is weighed.

Detected clinical pattern

Urgent Review Finding

A safety rule calls for urgent clinical assessment. Read the safety findings first.

  • Pattern: low testosterone single sample

Why this pattern was identified

  • Low total testosterone, not confirmed. 90 ng/dL is below 300 ng/dL (AUA); second sample not entered. Confirmation on a separate fasting morning sample is required before it is acted on.

Recommended next steps

For physician consideration. Urgent review always comes first.

  1. 1Urgent assessment for a pituitary lesion.
  2. 2Consider pituitary imaging; review prolactin-raising drugs, hypothyroidism, renal failure and macroprolactinemia.
  3. 3Repeat a fasting morning total testosterone on a separate day.Endocrine Society 2018; AUA 2018.

Missing information

  • LH and FSH (to separate primary from secondary hypogonadism).
  • SHBG (for calculated free testosterone).
Evidence and rule trace · 4 rules

HG-02One low testosterone result, not yet confirmed

Inputs: total testosterone 90 ng/dL · second sample not entered

Low total testosterone on a single sample: confirmation is required.

HG-MISS-01Information needed to classify

Inputs: low testosterone · LH missing

Type of hypogonadism cannot be classified without gonadotropins and prolactin.

HG-07Hyperprolactinemia with low testosterone

Inputs: prolactin 310 ng/mL (upper limit 20) · low testosterone

Raised prolactin with low testosterone.

HG-SAFE-01Possible pituitary mass effect

Inputs: severe or new headache, or visual field loss · low testosterone

Urgent assessment: possible pituitary mass effect.

Evidence

  • EV-ES-TRT-2018 · Bhasin S, Brito JP, Cunningham GR, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744.
  • EV-AUA-2018 · Mulhall JP, Trost LW, Brannigan RE, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432.
  • EV-ES-PRL-2011 · Melmed S, Casanueva FF, Hoffman AR, et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2011;96(2):273-288.

Physician adjudication required. Clinical decision support for physician review. This output identifies laboratory patterns and cautions. It does not diagnose, find the cause, or recommend starting, stopping or dosing testosterone therapy. Physician adjudication is required.

More testosterone cases

All testosterone cases

The Clinical Intelligence Layer — transforming fragmented clinical information into structured intelligence for clinician review and action.

Contact Biod